(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 17.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Halozyme Therapeutics's revenue in 2025 is $1,084,306,000.On average, 5 Wall Street analysts forecast HALO's revenue for 2025 to be $151,362,951,306, with the lowest HALO revenue forecast at $146,211,574,180, and the highest HALO revenue forecast at $155,965,748,540. On average, 5 Wall Street analysts forecast HALO's revenue for 2026 to be $186,044,980,408, with the lowest HALO revenue forecast at $177,098,150,040, and the highest HALO revenue forecast at $193,456,970,000.
In 2027, HALO is forecast to generate $215,856,329,822 in revenue, with the lowest revenue forecast at $205,710,066,240 and the highest revenue forecast at $228,156,003,600.